BOS
PRTA icon

Bingham Osborn & Scarborough’s Prothena Corp PRTA Stock Holding History

Bingham Osborn & Scarborough’s Portfolio PRTA Stock Details PRTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-13,145
Closed -$349K – 110
2013
Q4 		$349K Buy
13,145
+306
+2% +$7.67K 0.05% 70
2013
Q3 		$260K Hold
12,839
– – 0.04% 76
2013
Q2 		$166K Buy
+12,839
New +$119K 0.03% 87

Other funds holding PRTA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Bingham Osborn & Scarborough's PRTA Position: Q1 2014 in Review

Bingham Osborn & Scarborough sold out of Prothena Corp (PRTA) in Q1 2014, closing a stake of 13,145 shares — an estimated $349K sold.

Bingham Osborn & Scarborough first reported a position in PRTA in Q2 2013 and held it in 3 quarters. The position peaked at $349K in Q4 2013. 118 funds tracked by Wall St. Rank hold PRTA as of Q1 2014.

  • Bingham Osborn & Scarborough reported no remaining Prothena Corp position as of Q1 2014 after selling out during the quarter.
  • Bingham Osborn & Scarborough sold 13,145 Prothena Corp shares in Q1 2014, an estimated $349K.
  • Bingham Osborn & Scarborough first reported a position in Prothena Corp in Q2 2013 and held it in 3 quarters.
  • Bingham Osborn & Scarborough's Prothena Corp position peaked at $349K in Q4 2013.
  • 118 funds tracked by Wall St. Rank held Prothena Corp as of Q1 2014.

Based on Bingham Osborn & Scarborough's 13F filing for Q1 2014, filed 7 May 2014.